Attana AB (NGM:ATANA) 3-Year RORE % : -32.35% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Attana AB 3-Year RORE %?

Attana AB NGM:ATANA 3-Year RORE % is -32.35 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Attana AB ranks worse than 68.16% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Attana AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was -32.35%.

The industry rank for Attana AB's 3-Year RORE % or its related term are showing as below:

NGM:ATANA's 3-Year RORE % is ranked worse than
68.16% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.98 vs NGM:ATANA: -32.35

Attana AB  (NGM:ATANA) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Attana AB 3-Year RORE % Related Terms


Attana AB 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Attana AB's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attana AB 3-Year RORE % Chart

Attana AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only 8.70 4.17 -13.04 -11.86 -35.90

Attana AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.18 -26.92 -34.04 -35.90 -32.35

NGM:ATANA vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Attana AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Attana AB 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Attana AB's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Attana AB's 3-Year RORE % falls into.



Attana AB 3-Year RORE % Calculation

Attana AB's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.004--0.015 )/( -0.034-0 )
=0.011/-0.034
=-32.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -32.35 mean?
Attana AB (NGM:ATANA) has a 3-Year RORE % of -32.35 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Attana AB and its competitors. According to the industry distribution chart, Attana AB ranks #137 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 68.2%.
Is Attana AB's 3-Year RORE % too high?
Attana AB's current 3-Year RORE % is -32.35. Based on the distribution chart, Attana AB ranks #137 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Attana AB's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Attana AB ranks #137 out of 201 companies for 3-Year RORE %. This places Attana AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Attana AB and its competitors. Attana AB's current 3-Year RORE % is -32.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attana AB stock overvalued right now?
Attana AB (NGM:ATANA) has a current 3-Year RORE % of -32.35. The current 3-Year RORE % is -32.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Attana AB (NGM:ATANA), the current 3-Year RORE % is -32.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attana AB Business Description

Address Bjornnasvagen 21, Stockholm, SWE, SE-114 19
Attana AB offers biologically relevant information to improve efficiency and performance of pharmaceutical drug development.